Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 11 (2), 81-88

Specific Features of Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis

Affiliations
Review

Specific Features of Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis

Fotios S Fousekis et al. J Clin Med Res.

Abstract

Primary sclerosing cholangitis (PSC) is a chronic and progressive disease of the biliary tract. PSC is strongly associated with inflammatory bowel disease (IBD), mainly with ulcerative colitis, and most PSC patients have underlying IBD. The pathophysiological interactions between IBD and PSC are unclear, although it seems that the patients with IBD and PSC have a distinct phenotype. IBD with coexisting PSC is more extensive and is characterized by milder activity compared to IBD alone. The coexistence of PSC increases the risk for colorectal cancer in IBD patients and lifelong annual surveillance colonoscopy is recommended. Also, liver transplantation (LT) for PSC may affect the course of IBD. In addition, the management of IBD after LT includes many specific problems. On the other hand, the effect of IBD on the natural history of PSC appears to be milder. However, IBD may increase the risk of postsurgical complications after LT and is a risk factor for recurrent PSC after LT. Overall, the coexistence of IBD with PSC changes the management, natural history and prognosis of both diseases.

Keywords: Colorectal cancer; Crohn’s disease; Inflammatory bowel disease; Primary sclerosing cholangitis; Ulcerative colitis.

Similar articles

See all similar articles

Cited by 1 PubMed Central articles

References

    1. Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(8):1982–1992. doi: 10.1097/MIB.0000000000000392. - DOI - PMC - PubMed
    1. Rojas-Feria M, Castro M, Suarez E, Ampuero J, Romero-Gomez M. Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver. World J Gastroenterol. 2013;19(42):7327–7340. doi: 10.3748/wjg.v19.i42.7327. - DOI - PMC - PubMed
    1. Mendes FD, Levy C, Enders FB, Loftus EV Jr, Angulo P, Lindor KD. Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol. 2007;102(2):344–350. doi: 10.1111/j.1572-0241.2006.00947.x. - DOI - PubMed
    1. Dyson JK, Beuers U, Jones DEJ, Lohse AW, Hudson M. Primary sclerosing cholangitis. Lancet. 2018;391(10139):2547–2559. doi: 10.1016/S0140-6736(18)30300-3. - DOI - PubMed
    1. Uko V, Thangada S, Radhakrishnan K. Liver disorders in inflammatory bowel disease. Gastroenterol Res Pract. 2012;2012:642923. doi: 10.1155/2012/642923. - DOI - PMC - PubMed

LinkOut - more resources

Feedback